DISCOUNT ZERTIFIKAT - BOSTON SCIENTIFIC | Real-time Bid/Ask 12:00:15 2024-06-20 EDT | ||
| 65.58 EUR / 65.59 EUR | +0.92% |
|
| Current month | +1.99% | ||
| 1 month | +2.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 65.27 | +0.43% |
| 24-06-19 | 64.99 | -0.41% |
| 24-06-18 | 65.26 | +0.08% |
| 24-06-17 | 65.21 | -0.41% |
| 24-06-14 | 65.48 | +0.48% |
Delayed Quote Börse Stuttgart
Last update June 20, 2024 at 08:29 am
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | Morgan Stanley |
| WKN | ME9AEJ |
| ISIN | DE000ME9AEJ3 |
| Date issued | 2024-02-27 |
| Maturity | 2024-12-20 (183 Days) |
| Parity | 1 : 1 |
| Emission price | 60.95 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 65.55 € |
|---|---|
| Lowest since issue | 58.23 € |
| Spread | 0.01 € |
| Spread % | 0.02% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
76.31
USD
Average target price
82
USD
Spread / Average Target
+7.45%
- Stock Market
- Certificates
- Certificat
